B. Riley Financial Issues Positive Forecast for Lantheus (NASDAQ:LNTH) Stock Price

Lantheus (NASDAQ:LNTH) had its price target increased by investment analysts at B. Riley Financial from $97.00 to $129.00 in a note issued to investors on Thursday,Benzinga reports. The firm presently has a “buy” rating on the medical equipment provider’s stock. B. Riley Financial’s price target would suggest a potential upside of 19.90% from the stock’s current price.

A number of other equities analysts have also issued reports on the stock. William Blair reissued an “outperform” rating on shares of Lantheus in a research report on Tuesday, March 17th. Citigroup reaffirmed an “outperform” rating on shares of Lantheus in a report on Friday, May 8th. Weiss Ratings reiterated a “hold (c)” rating on shares of Lantheus in a research note on Tuesday, May 26th. Citizens Jmp reissued a “market outperform” rating and set a $115.00 target price on shares of Lantheus in a report on Monday, June 29th. Finally, Jefferies Financial Group restated a “buy” rating and set a $110.00 target price on shares of Lantheus in a research report on Tuesday, March 17th. Eight research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $108.29.

Lantheus Stock Up 0.8%

Lantheus stock opened at $107.59 on Thursday. The business’s 50-day simple moving average is $99.78 and its two-hundred day simple moving average is $82.45. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.64 and a current ratio of 2.83. The company has a market cap of $7.00 billion, a PE ratio of 25.93 and a beta of -0.06. Lantheus has a fifty-two week low of $47.25 and a fifty-two week high of $111.86.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.25 by $0.21. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.The firm had revenue of $377.33 million during the quarter, compared to analysts’ expectations of $354.48 million. During the same period last year, the business posted $1.53 earnings per share. The company’s revenue for the quarter was up 1.2% compared to the same quarter last year. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Equities analysts anticipate that Lantheus will post 4.49 EPS for the current year.

Hedge Funds Weigh In On Lantheus

Institutional investors have recently made changes to their positions in the company. Western Wealth Management LLC purchased a new stake in Lantheus during the first quarter worth $25,000. Smartleaf Asset Management LLC increased its holdings in Lantheus by 63.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock valued at $34,000 after buying an additional 197 shares in the last quarter. Parallel Advisors LLC raised its position in shares of Lantheus by 122.6% in the fourth quarter. Parallel Advisors LLC now owns 541 shares of the medical equipment provider’s stock worth $36,000 after acquiring an additional 298 shares during the period. Osterweis Capital Management Inc. acquired a new position in shares of Lantheus in the second quarter worth about $36,000. Finally, Bessemer Group Inc. boosted its stake in shares of Lantheus by 221.2% during the 1st quarter. Bessemer Group Inc. now owns 514 shares of the medical equipment provider’s stock worth $39,000 after acquiring an additional 354 shares in the last quarter. 99.06% of the stock is owned by hedge funds and other institutional investors.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.